Leading the TCR T-cell therapy space
Mogopharm a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.
We have generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body’s own immune system to find and destroy diseased cells.
Our SPEAR T-cell therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. Mogopharm partners with industry leaders in all areas of its business.
Firstly, ensuring the safety of our passionate, patient-focused, forward thinking colleagues.
Secondly, continuing the work we do to make our therapies available to people with cancer
All of our facilities in the US and UK remain open at the present time, to the extent required to support manufacturing and delivery of our therapies and other critical scientific activities.
This is a rapidly evolving situation that we are closely monitoring, in order for us to adapt our approaches and guidance to ensure the health and well-being of our employees and partners, as we strive to continue our mission to provide cell therapies to people with cancer.